AG MADIGAN ANNOUNCES $71 MILLION SETTLEMENT WITH AMGEN OVER DECEPTIVE PRESCRIPTION MARKETING
Chicago — Attorney General Lisa Madigan, along with the Attorneys General of 48 other states today announced a $71 million settlement with Amgen, Inc. for its deceptive marketing of the prescription biologic medications Aranesp and Enbrel.
Led by Madigan and her Oregon counterpart, the Attorneys General filed the joint lawsuit and consent order with Amgen, Inc. to resolve allegations that Amgen deceptively promoted the two biologic medications. Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is used to treat a number of conditions, including plaque psoriasis.
The complaint alleges that Amgen violated state consumer protection laws by:
“Companies marketing medicines to consumers have a responsibility to be accurate about uses, dosages and side effects,” said Madigan. “Mischaracterizing that information can prevent consumers from receiving the relief they need, or have more serious health consequences.”
The consent order prohibits Amgen from:
Along with the consent order limiting Amgen’s future conduct, Illinois will receive more than $3 million as part of the settlement.
The other states participating in the settlement are Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
Assistant Attorney General E. Paige Boggs handled this case for Madigan’s Consumer Fraud Bureau, which protects Illinois consumers and businesses that have been victimized by fraud, deception and unfair business practices.